|
1.
|
Schröder FH, Hugosson J, Roobol MJ,
Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H,
Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH,
Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss
SM, de Koning HJ and Auvinen A; ERSPC Investigators: Screening and
prostate-cancer mortality in a randomized European study. N Engl J
Med. 13:1320–1328. 2009.PubMed/NCBI
|
|
2.
|
Andriole GL, Crawford ED, Grubb RL III,
Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding
DJ, Weissfeld JL, Yokochi LA, O’Brien B, Clapp JD, Rathmell JM,
Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF,
Prorok PC, Gohagan JK and Berg CD; PLCO Project Team: Mortality
results from a randomized prostate-cancer screening trial. N Engl J
Med. 13:1310–1319. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Vollmer RT, Kantoff PW, Dawson NA and
Vogelzang NJ: A prognostic score for hormone-refractory prostate
cancer: analysis of two Cancer and Leukemia Group B studies. Clin
Cancer Res. 5:831–837. 1999.PubMed/NCBI
|
|
4.
|
Halabi S, Small EJ, Kantoff PW, Kattan MW,
Kaplan EB, Dawson NA, Levine EG, Blumenstein BA and Vogelzang NJ:
Prognostic model for predicting survival in men with
hormone-refractory metastatic prostate cancer. J Clin Oncol.
21:1232–1237. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Yagoda A and Petrylak D: Cytotoxic
chemotherapy for advanced hormone-resistant prostate cancer.
Cancer. 71:1098–1109. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Ferro MA, Gillatt D, Symes MO and Smith
PJ: High-dose intravenous estrogen therapy in advanced prostatic
carcinoma. Use of serum prostate-specific antigen to monitor
response. Urology. 34:134–138. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Smith DC, Dunn RL, Strawderman MS and
Pienta KJ: Change in serum prostate-specific antigen as a marker of
response to cytotoxic therapy for hormone-refractory prostate
cancer. J Clin Oncol. 16:1835–1843. 1998.PubMed/NCBI
|
|
8.
|
Kelly WK, Scher HI, Mazumdar M, Vlamis V,
Schwartz M and Fossa SD: Prostate-specific antigen as a measure of
disease outcome in metastatic hormone-refractory prostate cancer. J
Clin Oncol. 11:607–615. 1993.PubMed/NCBI
|
|
9.
|
Scher HI, Kelly WM, Zhang ZF, Ouyang P,
Sun M, Schwartz M, Ding C, Wang W, Horak ID and Kremer AB:
Post-therapy serum prostate-specific antigen level and survival in
patients with androgen-independent prostate cancer. J Natl Cancer
Inst. 91:244–251. 1999. View Article : Google Scholar
|
|
10.
|
Petrylak DP, Ankerst DP, Jiang CS, Tangen
CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Kohli M,
Benson MC, Small EJ, Raghavan D and Crawford ED: Evaluation of
prostate-specific antigen declines for surrogacy in patients
treated on SWOG 99-16. J Natl Cancer Inst. 98:516–521. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Bubley GJ, Carducci M, Dahut W, et al:
Eligibility and response guidelines for phase II clinical trials in
androgen-independent prostate cancer: recommendations from the
Prostate-Specific Antigen Working Group. J Clin Oncol.
17:3461–3467. 1999.
|
|
12.
|
Scher HI, Halabi S, Tannock I, et al:
Prostate Cancer Clinical Trials Working Group: design and end
points of clinical trials for patients with progressive prostate
cancer and castrate levels of testosterone: recommendations of the
Prostate Cancer Clinical Trials Working Group. J Clin Oncol.
26:1148–1159. 2008. View Article : Google Scholar
|
|
13.
|
Petrylak DP, Tangen CM, Hussain MH, Lara
PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M,
Benson MC, Small EJ, Raghavan D and Crawford ED: Docetaxel and
estramustine compared with mitoxantrone and prednisone for advanced
refractory prostate cancer. N Engl J Med. 351:1513–1520. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Tannock IF, de Wit R, Berry WR, Horti J,
Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I,
Rosenthal MA and Eisenberger MA; TAX 327 Investigators: Docetaxel
plus prednisone or mitoxantrone plus prednisone for advanced
prostate cancer. N Engl J Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Winquist E, Waldron T, Berry S, Ernst DS,
Hotte S and Lukka H: Non-hormonal systemic therapy in men with
hormone-refractory prostate cancer and metastases: a systematic
review from the Cancer Care Ontario Program in Evidence-based
Care’s Genitourinary Cancer Disease Site Group. BMC Cancer.
6:1122006.PubMed/NCBI
|
|
16.
|
Hudes G, Einhorn L, Ross E, Balsham A,
Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R,
Monaco F, Hanna M and Roth B: Vinblastine versus vinblastine plus
oral estramustine phosphate for patients with hormone-refractory
prostate cancer: a Hoosier Oncology Group and Fox Chase Network
phase III trial. J Clin Oncol. 17:3160–3166. 1999.
|
|
17.
|
Iversen P, Rasmussen F, Asmussen C,
Christensen IJ, Eickhoff J, Klarskov P, Larsen E, Mogensen P,
Mommsen S and Rosenkilde P: Estramustine phosphate versus placebo
as second line treatment after orchiectomy in patients with
metastatic prostate cancer: DAPROCA study 9002. Danish Prostatic
Cancer Group. J Urol. 157:929–934. 1997. View Article : Google Scholar
|
|
18.
|
Abratt RP, Brune D, Dimopoulos MA, Kliment
J, Breza J, Selvaggi FP, Beuzeboc P, Demkow T and Oudard S:
Randomised phase III study of intravenous vinorelbine plus hormone
therapy versus hormone therapy alone in hormone-refractory prostate
cancer. Ann Oncol. 15:1613–1621. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Kantoff PW, Halabi S, Conaway M, Picus J,
Kirshner J, Hars V, Trump D, Winer EP and Vogelzang NJ:
Hydrocortisone with or without mitoxantrone in men with
hormone-refractory prostate cancer: results of the Cancer and
Leukemia Group B 9182 study. J Clin Oncol. 17:2506–2513.
1999.PubMed/NCBI
|
|
20.
|
Berry W, Dakhil S, Modiano M, Gregurich M
and Asmar L: Phase III study of mitoxantrone plus low dose
prednisone versus low dose prednisone alone in patients with
asymptomatic hormone refractory prostate cancer. J Urol.
168:2439–2443. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Tannock IF, Osoba D, Stockler MR, Ernst
DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin
CM and Murphy KC: Chemotherapy with mitoxantrone plus prednisone or
prednisone alone for symptomatic hormone-resistant prostate cancer:
a Canadian randomized trial with palliative end points. J Clin
Oncol. 14:1756–1764. 1996.
|
|
22.
|
Petrioli R, Fiaschi AI, Francini E,
Pascucci A and Francini G: The role of doxorubicin and epirubicin
in the treatment of patients with metastatic hormone-refractory
prostate cancer. Cancer Treat Rev. 34:710–718. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Torti FM, Aston D, Lum BL, Kohler M,
Williams R, Spaulding JT, Shortliffe L and Freiha FS: Weekly
doxorubicin in endocrine-refractory carcinoma of the prostate. J
Clin Oncol. 1:477–482. 1983.PubMed/NCBI
|
|
24.
|
Delaere KP, Leliefeld H, Peulen F, Stapper
EW, Smeets J and Wils J: Phase II study of epirubicin in advanced
hormone-resistant prostatic carcinoma. Br J Urol. 70:641–642. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Francini G, Petrioli R, Manganelli A,
Cintorino M, Marsili S, Aquino A and Mondillo S: Weekly
chemotherapy in advanced prostatic cancer. Br J Cancer.
67:1430–1436. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Petrioli R, Fiaschi AI, Pozzessere D,
Messinese S, Sabatino M, Marsili S, Correale P, Manganelli A,
Salvestrini F and Francini G: Weekly epirubicin in patients with
hormone-resistant prostate cancer. Br J Cancer. 87:720–725. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Neri B, Barbagli G, Bellesi P, Di Loro R,
Lombardi V, Lombardo C, Magrini T, Mottola A, Nicita G, Palminteri
E, Ponchietti R, Raugei A and Intini C: Weekly epidoxorubicin
therapy in hormone-refractory metastatic prostate cancer.
Anticancer Res. 17:3817–3820. 1997.PubMed/NCBI
|
|
28.
|
Van Andel G, Fernandez de Moral P, Caris
CT, Carpentier P, Wils J, de Bruin MJ, Witjes JA, Debruyne FM and
Witjes WP: A randomized study comparing epirubicin in a 4-weekly
versus a weekly intravenous regimen in patients with metastatic,
hormone resistant, prostatic carcinoma: effects on health related
quality of life. World J Urol. 21:177–182. 2003.
|
|
29.
|
Laurie JA, Hahn RG, Therneau TM, Patel SR,
Mailliard JA, Windschitl HE, Twito DI, Morton RF and Krook JE:
Chemotherapy for hormonally refractory advanced prostate carcinoma.
A comparison of combined versus sequential treatment with mitomycin
C, doxorubicin, and 5-fluorouracil. Cancer. 69:1440–1444. 1992.
View Article : Google Scholar
|
|
30.
|
Stephens RL, Vaughn C, Lane M, Costanzi J,
O’Bryan R, Balcerzak SP, Levin H, Frank J and Coltman CA Jr:
Adriamycin and cyclophosphamide versus hydroxyurea in advanced
prostatic cancer/ A randomized Southwest Oncology Group study.
Cancer. 53:406–410. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Saxman S, Ansari R, Drasga R, Miller M,
Wheeler B, McClean J and Einhorn L: Phase III trial of
cyclophosphamide versus cyclophosphamide, doxorubicin, and
methotrexate in hormone-refractory prostatic cancer. A Hoosier
Oncology Group Study. Cancer. 70:2488–2492. 1992. View Article : Google Scholar
|
|
32.
|
Bramwell VH, Mouridsen HT, Santoro A, et
al: Cyclophosphamide versus ifosfamide: a randomized phase II trial
in adult soft-tissue sarcomas. The European Organization for
Research and Treatment of Cancer [EORTC], Soft Tissue and Bone
Sarcoma Group. Cancer Chemother Pharmacol. 31(Suppl 2): 180–184.
1993.PubMed/NCBI
|
|
33.
|
Blum RH, Edmonson J, Ryan L and Pelletier
L: Efficacy of ifosfamide in combination with doxorubicin for the
treatment of metastatic soft-tissue sarcoma. The Eastern
Cooperative Oncology Group. Cancer Chemother Pharmacol. 31(Suppl
2): 238–240. 1993.PubMed/NCBI
|
|
34.
|
Hervonen Lehtinen T, Tammela TL and
Kellokumpu-Lehtinen P: A randomised dose finding phase II study on
ifosfamide in metastatic hormone-refractory prostate cancer (HRPC).
J Exp Clin Cancer Res. 21:177–180. 2002.PubMed/NCBI
|
|
35.
|
Williamson SK, Wolf MK, Eisenberger MA,
O’Rourke MA, Brannon W and Crawford ED: Phase II evaluation of
ifosfamide/mesna in metastatic prostate cancer. A Southwest
Oncology Group study. Am J Clin Oncol. 19:368–370. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Petrioli R, Paolelli L, Francini E,
Manganelli A, Salvestrini F and Francini G: Weekly docetaxel and
epirubicin in treatment of advanced hormone-refractory prostate
cancer. Urology. 69:142–146. 2007. View Article : Google Scholar : PubMed/NCBI
|
